NEJM Evidence Publishes Results for ImmunityBio’s QUILT 3.032 Registrational Trial of IL-15 Superagonist N-803 Plus BCG in Patients with Bladder Cancer
ImmunityBio's QUILT 3.032 trial results for N-803 plus BCG show promising efficacy for bladder cancer patients. In the carcinoma in situ cohort, 71% achieved complete response (CR) with a median duration of 26.6 months. The treatment demonstrated a 90% probability of avoiding cystectomy in responders. In the NMIBC cohort, 55% remained disease-free at 12 months. The FDA is reviewing the Biologics License Application for this combination therapy, with a decision expected by May 23, 2023. N-803's safety profile was comparable to BCG alone, indicating its potential role in treating BCG-unresponsive bladder cancer.
- 71% complete response rate in high-risk carcinoma in situ cohort.
- Median duration of response is 26.6 months.
- 90% probability of avoiding cystectomy over 24 months in responders.
- 55% disease-free rate at 12 months in the NMIBC cohort.
- Safety profile comparable to BCG alone.
- None.
-
Primary endpoint met in high-risk carcinoma in situ (CIS) cohort with
71% complete response rate (CR) with a median duration of response of 26.6 months, a53% CR rate at 24 months and a safety profile comparable to BCG alone -
This novel IL-15 superagonist N-803 – referred to as nogpendekin alfa inbakicept (NAI) in the manuscript - acts synergistically with BCG with a
90% probability of avoiding cystectomy over 24 months in responders -
Primary endpoint also met in papillary non-muscle invasive bladder cancer (NMIBC) cohort with
55% remaining disease free at 12 months -
The
Food and Drug Administration (FDA) is currently reviewing the Biologics License Application (BLA) for N-803 plus BCG for the treatment of NMIBC CIS with a Prescription Drug User Fee Act (PDUFA) date ofMay 23, 2023
The published results demonstrate that in patients with BCG-unresponsive NMIBC CIS and papillary disease, BCG plus N-803 (referred to as NAI) CRs were achieved with a persistence of effect with
“The peer review and publication of data in NEJM Evidence highlights the significance of the positive results of the QUILT 3.032 trial in patients with BCG-unresponsive NMIBC,” said
Patients with intermediate or high-risk NMIBC typically receive a treatment of transurethral resection of the bladder tumor (TURBT) followed by BCG intravesical instillation. However, cancer will recur in
Treatment options for BCG-unresponsive NMIBC patients are limited. Pembrolizumab was approved by the FDA for this indication in 2020, based on findings from the KEYNOTE-057 study in which the CR rate in NMIBC CIS patients was
In patients who received intravesical N-803 plus BCG (cohort A), a CR was achieved in 58 (
In patients with BCG-unresponsive high-grade Ta/T1 papillary NMIBC who received N-803 plus BCG (cohort B), the Kaplan–Meier–estimated disease-free survival (DFS) rate was
Most adverse events for patients receiving BCG plus NAI were grade 1 to 2 (
About the QUILT 3.032 Trial
In this phase 2/3, open-label, multicenter study, patients with BCG-unresponsive bladder carcinoma in situ (CIS) with or without Ta/T1 papillary disease were treated with intravesical N-803 plus BCG (cohort A) or N-803 alone (cohort C). Patients with BCG-unresponsive high-grade Ta/T1 papillary NMIBC also received N-803 plus BCG (cohort B). The primary end point was the incidence of CR at the 3- or 6-month assessment visit for cohorts A and C, and the disease-free survival (DFS) rate at 12 months for cohort B. Durability, cystectomy avoidance, progression-free survival, disease-specific survival, and overall survival were secondary end points for cohort A.
The results of this phase 2/3 study are currently being reviewed by the FDA, and a decision from the FDA regarding approval for use of the biologics N-803 plus BCG in adults with BCG-unresponsive NMIBC CIS is expected on
ImmunityBio’s IL-15 superagonist N-803
The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of the natural killer (NK) and T cells. N-803 (generic name nogapendekin alfa inbakicept or NAI) is a novel IL-15 superagonist complex consisting of an IL-15 mutant (IL-15N72D) bound to an IL-15 receptor α/IgG1 Fc fusion protein. Its mechanism of action is direct specific stimulation of CD8+ T cells and NK cells through beta gamma T-cell receptor binding (not alpha) while avoiding T-reg stimulation. N-803 has improved pharmacokinetic properties, longer persistence in lymphoid tissues and enhanced anti-tumor activity compared to native, non-complexed IL-15 in vivo.
N-803 has been studied in more than 700 patients in multiple phase 1 and 2 trials in both liquid and solid tumors. In addition to the study in NMIBC, it is currently being studied in trials for pancreatic cancer, non-small-cell lung cancer, non-Hodgkin’s lymphoma, and HIV.
N-803 has received both Breakthrough Therapy and Fast Track designations by the FDA for the treatment of BCG-unresponsive NMIBC CIS, as well as Fast Track designation for BCG-unresponsive NMIBC papillary and BCG-naïve NMIBC CIS. However, it is important to note such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval. Seminal patents covering intravesical administration of BCG and N-803 were issued (US 11,173,191 B2 and US 9,925,247 B2) providing term coverage until 2035.
About
ImmunityBio’s clinical pipeline consists of 27 clinical trials—18 of which are in phase 2 or 3 development—across 13 indications in liquid and solid tumors (including bladder, pancreatic, and lung cancers) and infectious diseases (including SARS-CoV-2 and HIV). N-803 (Anktiva™), ImmunityBio’s lead cytokine fusion protein, is a novel IL-15 superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the
The company has established GMP manufacturing capacity at scale with cutting-edge cell therapy manufacturing expertise and ready-to-scale facilities, as well as extensive and seasoned R&D, clinical trial, and regulatory operations, and development teams. For more information, please visit: www.immunitybio.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding data from the clinical trials for certain of ImmunityBio’s product candidates, the regulatory review process and timing thereof, potential implications to be drawn from the QUILT 3.032 and other studies, whether the described mechanism of action contributes to response rate and duration, potential commercialization of ImmunityBio’s product candidates, ImmunityBio’s product candidates as compared to existing treatment options, intellectual property protection, and clinical trial advancements and data, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “indicate,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110006024/en/
Investors
844-696-5235, Option 5
Sarah.Singleton@immunitybio.com
Media
Salutem
978-360-3151
Katie.Dodge@salutemcomms.com
Source:
FAQ
What were the results of the QUILT 3.032 trial for IBRX?
What is the significance of the 90% probability reported in the IBRX trial?
When is the FDA expected to make a decision regarding IBRX's BLA?